macimorelin (Macrilen) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class

Active Ingredient History

  • Now
Macimorelin (AEZS 130) is an orally active, small-molecule, peptidomimetic growth hormone secretagogue receptor (GHSR1A) agonist (ghrelin analogue), being developed by AEterna Zentaris for the diagnosis of adult growth hormone deficiency (AGHD; somatotropin deficiency), and for the treatment of cachexia associated with chronic disease such as AIDS and cancer. Macimorelin was approved by the FDA in December 2017 under the market name Macrilen for oral solution. Macimorelin stimulates GH release by activating growth hormone secretagogue receptors present in the pituitary and hypothalamus. Macimorelin has been granted orphan drug designation by the FDA for diagnosis of AGHD.   NCATS

  • SMILES: CC(=O)O.CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc3c[nH]c4ccccc34)NC=O
  • Mol. Mass: 534.62
  • ALogP: 1.84
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$56.1407 - $73.8693
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

aezs-130 | aib-dtrp-dgtrp-cho | aib-trp-gtrp-cho | aminoisobutyryl-tryptophyl-tryptophanamine-formyl | ard-07 | ep-01572 | ep1572 | ep 1572 | ep-1572 | jmv1843 | jmv 1843 | jmv-1843 | macimorelin | macimorelin acetate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue